New York State Common Retirement Fund Buys 2,060 Shares of Edwards Lifesciences Co. (NYSE:EW)

New York State Common Retirement Fund lifted its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 0.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 826,477 shares of the medical research company’s stock after purchasing an additional 2,060 shares during the quarter. New York State Common Retirement Fund owned 0.14% of Edwards Lifesciences worth $61,184,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at approximately $30,000. FSA Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at approximately $30,000. Prospera Private Wealth LLC bought a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at approximately $32,000. Avior Wealth Management LLC grew its holdings in shares of Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares during the last quarter. Finally, Roble Belko & Company Inc bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at approximately $46,000. 79.46% of the stock is owned by institutional investors.

Insider Activity

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the sale, the chief financial officer now owns 30,561 shares in the company, valued at approximately $2,315,301.36. The trade was a 26.91 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now owns 23,189 shares of the company’s stock, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,489 shares of company stock worth $2,002,829 in the last quarter. 1.27% of the stock is owned by corporate insiders.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $74.73 on Thursday. The company has a fifty day moving average of $72.84 and a 200-day moving average of $69.82. The firm has a market capitalization of $44.07 billion, a P/E ratio of 10.72, a P/E/G ratio of 4.92 and a beta of 1.10. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on EW shares. Canaccord Genuity Group lifted their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research report on Thursday, February 13th. Robert W. Baird cut their target price on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. JPMorgan Chase & Co. lifted their target price on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Truist Financial reiterated a “hold” rating and set a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $85.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.